EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Immunic (NASDAQ:IMUX) and maintained a price target of $17.
October 22, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Immunic, maintaining a price target of $17. This suggests confidence in the company's future performance and potential upside in its stock price.
The reaffirmation of a Buy rating and a $17 price target by EF Hutton indicates a positive outlook for Immunic's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100